Rani Therapeutics Holdings, Inc. Class A ( (RANI) ) has released its Q2 earnings. Here is a breakdown of the information Rani Therapeutics Holdings, Inc. Class A presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing oral delivery technologies for biologics and drugs, offering an alternative to injections, with its innovative RaniPill capsule platform. In its latest earnings report for the quarter ending June 30, 2025, Rani Therapeutics highlighted its ongoing financial challenges and strategic developments. The company reported a net loss of $11.2 million for the quarter, with total operating expenses amounting to $10.5 million, primarily driven by research and development and general administrative costs. Despite the financial losses, Rani Therapeutics continues to advance its RaniPill technology and expand its product portfolio. The company also announced a collaboration with ProGen Co., Ltd. to develop a weight management product using its RaniPill HC device. Looking ahead, Rani Therapeutics remains focused on securing additional funding to support its operations and clinical trials, as it works towards achieving regulatory approvals and commercializing its innovative oral delivery solutions.